Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma.

Kwon JH, Kim J, Park JY, Hong SM, Park CW, Hong SJ, Park SY, Choi YJ, Do IG, Joh JW, Kim DS, Choi KY.

Clin Cancer Res. 2010 Nov 15;16(22):5511-21. doi: 10.1158/1078-0432.CCR-10-0825. Epub 2010 Sep 17.

2.
3.

Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma.

Li XR, Ji F, Ouyang J, Wu W, Qian LY, Yang KY.

Eur J Surg Oncol. 2006 Dec;32(10):1130-4. Epub 2006 Jun 27.

PMID:
16806792
4.

Decreased ID2 promotes metastatic potentials of hepatocellular carcinoma by altering secretion of vascular endothelial growth factor.

Tsunedomi R, Iizuka N, Tamesa T, Sakamoto K, Hamaguchi T, Somura H, Yamada M, Oka M.

Clin Cancer Res. 2008 Feb 15;14(4):1025-31. doi: 10.1158/1078-0432.CCR-07-1116.

5.

Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma.

Fang F, Luo LB, Tao YM, Wu F, Yang LY.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):409-16. doi: 10.1158/1055-9965.EPI-08-0575.

6.

High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy.

Liu F, Zhang Y, Peng Z, Gao H, Xu L, Chen M.

J Transl Med. 2012 Jul 2;10:135. doi: 10.1186/1479-5876-10-135.

7.

ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.

Lin SY, Pan HW, Liu SH, Jeng YM, Hu FC, Peng SY, Lai PL, Hsu HC.

Clin Cancer Res. 2008 Aug 1;14(15):4814-20. doi: 10.1158/1078-0432.CCR-07-5262.

8.

Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma.

Morinaga S, Nakamura Y, Ishiwa N, Yoshikawa T, Noguchi Y, Yamamoto Y, Rino Y, Imada T, Takanashi Y, Akaike M, Sugimasa Y, Takemiya S.

Oncol Rep. 2004 Dec;12(6):1189-94.

PMID:
15547736
9.

Downregulation of MAGI1 associates with poor prognosis of hepatocellular carcinoma.

Zhang G, Liu T, Wang Z.

J Invest Surg. 2012 Apr;25(2):93-9. doi: 10.3109/08941939.2011.606875. Epub 2011 Sep 26.

PMID:
21942217
10.

Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma.

Dong ZZ, Yao DF, Yao M, Qiu LW, Zong L, Wu W, Wu XH, Yao DB, Meng XY.

Hepatobiliary Pancreat Dis Int. 2008 Jun;7(3):288-95.

11.

Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis.

Sera T, Hiasa Y, Mashiba T, Tokumoto Y, Hirooka M, Konishi I, Matsuura B, Michitaka K, Udaka K, Onji M.

Eur J Cancer. 2008 Mar;44(4):600-8. doi: 10.1016/j.ejca.2008.01.008. Epub 2008 Feb 5.

PMID:
18255279
12.

[Expression of vascular endothelial growth factor (VEGF) family members and prognosis after hepatic resection in HBV-related hepatocellular carcinoma].

Moon JI, Kim JM, Jung GO, Chun JM, Choi GS, Park JB, Kwon CH, Kim SJ, Jo JW.

Korean J Hepatol. 2008 Jun;14(2):185-96. doi: 10.3350/kjhep.2008.14.2.185. Korean.

PMID:
18617766
13.

dUTP pyrophosphatase expression correlates with a poor prognosis in hepatocellular carcinoma.

Takatori H, Yamashita T, Honda M, Nishino R, Arai K, Yamashita T, Takamura H, Ohta T, Zen Y, Kaneko S.

Liver Int. 2010 Mar;30(3):438-46. doi: 10.1111/j.1478-3231.2009.02177.x. Epub 2009 Nov 30.

PMID:
19968781
14.

Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection.

Yang XR, Xu Y, Shi GM, Fan J, Zhou J, Ji Y, Sun HC, Qiu SJ, Yu B, Gao Q, He YZ, Qin WZ, Chen RX, Yang GH, Wu B, Lu Q, Wu ZQ, Tang ZY.

Clin Cancer Res. 2008 Jun 15;14(12):3850-9. doi: 10.1158/1078-0432.CCR-07-4338.

15.

Liver-intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virus-positive hepatocellular carcinoma.

Ding ZB, Shi YH, Zhou J, Shi GM, Ke AW, Qiu SJ, Wang XY, Dai Z, Xu Y, Fan J.

Cancer. 2009 Oct 15;115(20):4753-65. doi: 10.1002/cncr.24513.

16.

Clinical significance of decreased nidogen-2 expression in the tumor tissue and serum of patients with hepatocellular carcinoma.

Cheng ZX, Huang XH, Wang Q, Chen JS, Zhang LJ, Chen XL.

J Surg Oncol. 2012 Jan;105(1):71-80. doi: 10.1002/jso.22047. Epub 2011 Aug 3.

PMID:
21815147
17.

CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery.

Yang XR, Xu Y, Yu B, Zhou J, Li JC, Qiu SJ, Shi YH, Wang XY, Dai Z, Shi GM, Wu B, Wu LM, Yang GH, Zhang BH, Qin WX, Fan J.

Clin Cancer Res. 2009 Sep 1;15(17):5518-27. doi: 10.1158/1078-0432.CCR-09-0151. Epub 2009 Aug 25.

18.

High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistance.

Wu ZB, Cai L, Lin SJ, Xiong ZK, Lu JL, Mao Y, Yao Y, Zhou LF.

Neuro Oncol. 2013 Sep;15(9):1264-75. doi: 10.1093/neuonc/not078. Epub 2013 Jul 4.

19.
20.

[Focal adhesion kinase mRNA overexpression in hepatocellular carcinoma HCC) and correlation thereof with prognosis of HCC].

Yuan Z, Fan J, Wu ZQ, Zhou J, Qiu SJ.

Zhonghua Yi Xue Za Zhi. 2007 May 15;87(18):1256-9. Chinese.

PMID:
17686260

Supplemental Content

Support Center